GKCAS 2022 Annual Meeting

April 9, 2022

Didactic lectures given by speakers in the therapeutic areas of SCID, Mast Cell Activation, WHIM Syndrome, Eosinophilic Myocarditis and much more.

Accreditation   
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Greater Kansas City Allergy Society (GKCAS).  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 3.25 contact hours.

 

 

 

 

 

Target Audience

Primary care physicians
Allied healthcare providers

 

 

 

 

 

Learning Objectives

At the conclusion of this activity learners should be able to:

  1. Identify when a biologic agent is indicated for asthma
  2. Select the most appropriate biologic for individual patients.
  3. Able to diagnose AERD
  4. Identify the best management option for individual AERD patients
  5. Recognize non-IgE-mediated food reactions and how to manage these disorders.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

Ambulatory procedure centers

  • Blood banks
  • Diagnostic labs that do not sell proprietary products
  • Electronic health records companies
  • Government or military agencies
  • Group medical practices
  • Health law firms
  • Health profession membership organizations
  • Hospitals or healthcare delivery systems
  • Infusion centers
  • Insurance or managed care companies
  • Nursing homes
  • Pharmacies that do not manufacture proprietary compounds
  • Publishing or education companies
  • Rehabilitation centers
  • Schools of medicine or health science universities
  • Software or game developers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been mitigated

 

Course summary
Available credit: 
  • 3.25 AMA PRA Category 1 Credit™
  • 3.25 Attendance
  • 3.25 CBRN
Course opens: 
04/09/2022
Course expires: 
12/31/2024
Event starts: 
04/09/2022 - 8:00am CDT
Event ends: 
04/09/2022 - 11:45am CDT
Rating: 
0

Mariana Castells
Researcher: Blueprints Medicine- PI for two drug investigation studies (BLU-285 and BLU-263) which are tyrosine kinase inhibitors used to treat Mastocytosis
Researcher: NIH- PI for COVID Vaccine study

Kathleen Sullivan
Advisor: Immune Deficiency Foundation
Advisor: Enzyvant


The following have no relevant financial relationships to disclose:
Benjamin Rahoy
Andrea D’Mello
Hannah Neuhaus
Sean Stout
Jordan Pitt
 

 

Available Credit

  • 3.25 AMA PRA Category 1 Credit™
  • 3.25 Attendance
  • 3.25 CBRN
Please login or create an account to take this course.